Search

Your search keyword '"Duveau Nicolas"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Duveau Nicolas" Remove constraint Author: "Duveau Nicolas"
29 results on '"Duveau Nicolas"'

Search Results

1. Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based study

2. Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study

3. Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases

4. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study

5. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial

6. Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases

9. Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

10. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study

11. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study

13. Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

14. 1176 EFFECTIVENESS AND SAFETY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN'S DISEASE: A MULTICENTRE COHORT STUDY

15. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

16. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.

17. 946 DEEP REMISSION AT 1 YEAR IS NOT ASSOCIATED WITH BETTER OUTCOME IN CROHN'S DISEASE: LONG-TERM DATA FROM TAILORIX

18. Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease

19. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease

20. Mo1899 – Prognostic Factors for Long-Term Adalimumab Treatment in Crohn’s Disease : A Multicenter Experience

21. Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's Disease.

24. Early Biologic Treatment of Crohnʼs Disease Slows Progression Rate of Change of Lemann Index of Cumulative Bowel Damage: 2016 ACG Presidential Poster Award

25. Sa1960 Crohn's Disease Patients With High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab

27. Tu1953 Postoperative Clinical Recurrence Is Not Different in Crohn's Disease Patients Classified I2 on Rutgeerts Score With Lesions Confined to the Ileocolonic Anastomosis Compared to Patients With Lesions of the Neo-Terminal Ileum

Catalog

Books, media, physical & digital resources